SG11201907914QA - Polypeptide, polypeptide fragment, derivative thereof, and applications thereof - Google Patents
Polypeptide, polypeptide fragment, derivative thereof, and applications thereofInfo
- Publication number
- SG11201907914QA SG11201907914QA SG11201907914QA SG11201907914QA SG11201907914QA SG 11201907914Q A SG11201907914Q A SG 11201907914QA SG 11201907914Q A SG11201907914Q A SG 11201907914QA SG 11201907914Q A SG11201907914Q A SG 11201907914QA SG 11201907914Q A SG11201907914Q A SG 11201907914QA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide
- derivative
- applications
- fragment
- polypeptide fragment
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000012634 fragment Substances 0.000 title abstract 3
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710115604.4A CN106860855B (zh) | 2017-03-01 | 2017-03-01 | 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用 |
| CN201710677602.4A CN109384830B (zh) | 2017-08-09 | 2017-08-09 | 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用 |
| PCT/CN2018/077492 WO2018157807A1 (zh) | 2017-03-01 | 2018-02-28 | 多肽、多肽片段及其衍生物与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907914QA true SG11201907914QA (en) | 2019-09-27 |
Family
ID=63369746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907914QA SG11201907914QA (en) | 2017-03-01 | 2018-02-28 | Polypeptide, polypeptide fragment, derivative thereof, and applications thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12011475B2 (enExample) |
| EP (1) | EP3590527A4 (enExample) |
| JP (1) | JP6965362B2 (enExample) |
| KR (1) | KR102368159B1 (enExample) |
| AU (1) | AU2018227737B2 (enExample) |
| CA (1) | CA3054839C (enExample) |
| IL (1) | IL268971B2 (enExample) |
| SG (1) | SG11201907914QA (enExample) |
| WO (1) | WO2018157807A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7302120B2 (ja) * | 2015-10-27 | 2023-07-04 | タイペイ メディカル ユニバーシティ | 線維症疾患の治療及び／又は予防用インドリン誘導体 |
| CN112386678B (zh) * | 2019-08-13 | 2023-07-07 | 成都惠泰生物医药有限公司 | 多肽或其衍生物的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9509957D0 (en) * | 1995-05-17 | 1995-07-12 | Khalil Nasreen | Post-translational activation of tgf-1 involving the tsp-1 receptor cd36 |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| DK1105409T3 (da) | 1999-05-17 | 2006-07-03 | Conjuchem Inc | Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter |
| AU2002347182A1 (en) | 2001-12-18 | 2003-06-30 | Mondobiotech Licensing Out Ag | Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
| WO2009039966A2 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009043525A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of the combination of gluten exorphin c and cd36 as a therapeutic agent |
| KR20130087585A (ko) * | 2010-11-24 | 2013-08-06 | 에프. 호프만-라 로슈 아게 | 저도 염증을 검출하는 방법 |
| LT2714735T (lt) | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| US10035823B2 (en) | 2014-09-29 | 2018-07-31 | The Regents Of The University Of California | Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions |
| CN104313028A (zh) | 2014-09-30 | 2015-01-28 | 北京生科东方科技有限公司 | 抗类风湿关节炎的小肽基因及其生产方法 |
| CN105061600A (zh) | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | 类风湿因子IgA抑制多肽及其应用 |
| CN106860855B (zh) * | 2017-03-01 | 2021-06-11 | 成都惠泰生物医药有限公司 | 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用 |
-
2018
- 2018-02-28 KR KR1020197028390A patent/KR102368159B1/ko active Active
- 2018-02-28 JP JP2019548059A patent/JP6965362B2/ja active Active
- 2018-02-28 IL IL268971A patent/IL268971B2/en unknown
- 2018-02-28 AU AU2018227737A patent/AU2018227737B2/en active Active
- 2018-02-28 CA CA3054839A patent/CA3054839C/en active Active
- 2018-02-28 US US16/490,543 patent/US12011475B2/en active Active
- 2018-02-28 WO PCT/CN2018/077492 patent/WO2018157807A1/zh not_active Ceased
- 2018-02-28 EP EP18760361.8A patent/EP3590527A4/en active Pending
- 2018-02-28 SG SG11201907914QA patent/SG11201907914QA/en unknown
-
2024
- 2024-05-07 US US18/656,641 patent/US20240390450A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3054839A1 (en) | 2018-09-07 |
| US20220072082A1 (en) | 2022-03-10 |
| WO2018157807A1 (zh) | 2018-09-07 |
| IL268971B1 (en) | 2023-09-01 |
| AU2018227737B2 (en) | 2021-04-01 |
| EP3590527A4 (en) | 2021-01-06 |
| JP6965362B2 (ja) | 2021-11-10 |
| CA3054839C (en) | 2023-08-29 |
| KR102368159B1 (ko) | 2022-03-03 |
| US12011475B2 (en) | 2024-06-18 |
| AU2018227737A2 (en) | 2020-01-30 |
| AU2018227737A1 (en) | 2019-10-17 |
| IL268971A (en) | 2019-10-31 |
| KR20190125373A (ko) | 2019-11-06 |
| US20240390450A1 (en) | 2024-11-28 |
| IL268971B2 (en) | 2024-01-01 |
| EP3590527A1 (en) | 2020-01-08 |
| JP2020509061A (ja) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| MX2018005720A (es) | Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello. | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| SG10201913575VA (en) | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | |
| NZ735044A (en) | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
| IN2014MU00303A (enExample) | ||
| PH12016501841A1 (en) | Immunosuppressant formulation | |
| WO2018226992A8 (en) | Tau aggregation inhibitors | |
| EP3625245A4 (en) | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| NZ728401A (en) | High purity oritavancin and method of producing same | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EP3676250A4 (en) | PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF | |
| MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
| TW201713686A (en) | Methods for preparing modified von Willebrand factor | |
| EP3205661A4 (en) | Hsp70-derived peptide, and method of manufacturing pharmaceutical composition, immunity inducer, and antigen-presenting cell for cancer treatment or prevention using the same | |
| MX2020003427A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| SG11201907914QA (en) | Polypeptide, polypeptide fragment, derivative thereof, and applications thereof | |
| MX2020001928A (es) | Proceso para la preparacion de tubulisinas e intermediarios de las mismas. |